Clinical Outcomes in Routine Evaluation Learning Disabilities

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

There was no significant difference in complete remission rate, CRS, NTX/ICANS, or infections between patients who received high-intensity versus low-intensity bridging chemotherapy, despite high-inte

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null

Disease burden at start of bridging chemotherapy (high vs low), disease burden prior to lymphodepleting chemotherapy (high vs low), and tumor debulking by bridging chemotherapy did not significantly a

Effect: null